With the American Society of Clinical Oncology (ASCO) winding down, staying on top of the key presentations is hard enough. So what about those that may have slipped under your radar over the final couple of days? FirstWord has rounded them up below:
Amgen's BiTE molecule AMG 420 in relapsed and/or refractory multiple myeloma
Amgen disclosed new data from a Phase I study of the BiTE molecule AMG 420 in 42 patients with relapsed and/or refractory multiple myeloma who had progression after at least two prior lines of treatment. The drug induced clinical responses in 13 patients across the dosing cohorts, with five of the six subjects that achieved a minimal residual disease-negative complete response treated at the maximum tolerated dose of 400 mcg/day.
The company added that at this dose, one patient achieved a very good partial response, and one achieved a partial response. Amgen added that the overall response rate in the 10 patients given AMG 420 at this dose was 70 percent. Results showed that the median duration of response was nine months, while the median time to response was one month, with 11 of 13 patients responding in the first cycle. For related analysis, read ViewPoints: ASCO19 – AMG 420 laying a foundation, but for what?
Takeda's TAK-788 in patients with non-small-cell lung cancer with EGFR exon 20 insertions
Takeda reported further results from a Phase I/II trial of TAK-788 in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumours harbour EGFR exon 20 insertion mutations. The company said ahead of the ASCO meeting that in 26 evaluable patients, the drug was associated with an objective response rate (ORR) of 54 percent, with all responses being partial responses.
At the conference, updated results showed in 28 patients, the ORR was 43 percent, with a disease control rate of 86 percent, while median progression-free survival (PFS) was 7.3 months. Takeda noted that in 16 patients without brain metastases at baseline, the ORR was 56 percent, with all patients responding to treatment with TAK-788, while median PFS was 8.1 months.
Novartis' MET inhibitor capmatinib in locally advanced or metastatic non-small-cell lung cancer
Novartis announced results from the Phase II GEOMETRY mono-1 trial demonstrating that capmatinib showed promise as a potential treatment option for patients with locally advanced or metastatic NSCLC that harbour MET exon-14 skipping mutation. The company gained global rights to the oral MET inhibitor under a deal with Incyte.
Results showed that in one cohort consisting of 28 treatment-naive patients, there was a 68 percent overall response rate, while in 69 previously-treated patients, 41 percent responded to treatment with capmatinib. Meanwhile, the median duration of response was 11.14 months and 9.72 months, respectively.
Daiichi Sankyo's TROP2 targeting antibody-drug conjugate DS-1062 in advanced non-small-cell lung cancer
Daiichi Sankyo reported preliminary results from a Phase I study of DS-1062, with the investigational TROP2 targeting antibody-drug conjugate leading to 10 partial responses in 35 evaluable patients with advanced NSCLC. The therapy is comprised of a humanised anti-TROP2 monoclonal antibody attached to a topoisomerase I inhibitor payload by a tetrapeptide-based linker.
According to the company, the median number of prior therapies for the partial responders is 3.5 and includes patients with prior EGFR or ALK inhibitors and checkpoint inhibitors. A maximum tolerated dose of DS-1062 has not yet been reached and 16 patients remain on-treatment. "These early results are encouraging as we have seen increased activity with higher doses of DS-1062," remarked lead investigator Jacob Sands, adding "additional study is warranted."
To read more Top Story articles, click here.